Craig Hallum Trims Inotiv (NASDAQ:NOTV) Target Price to $10.00

Inotiv (NASDAQ:NOTVFree Report) had its price target cut by Craig Hallum from $25.00 to $10.00 in a report issued on Thursday, Benzinga reports. They currently have a buy rating on the stock.

Separately, Jefferies Financial Group cut shares of Inotiv from a buy rating to a hold rating and cut their price objective for the company from $11.50 to $3.75 in a research report on Tuesday, May 14th.

View Our Latest Stock Report on Inotiv

Inotiv Stock Down 9.8 %

Shares of NOTV stock opened at $1.93 on Thursday. Inotiv has a 12-month low of $1.61 and a 12-month high of $11.42. The firm has a market capitalization of $50.12 million, a price-to-earnings ratio of -0.70 and a beta of 3.37. The firm has a fifty day moving average of $6.47 and a 200-day moving average of $4.80.

Institutional Investors Weigh In On Inotiv

Several institutional investors have recently added to or reduced their stakes in the stock. Blue Edge Capital LLC bought a new stake in Inotiv in the 1st quarter valued at $459,000. Lazard Asset Management LLC bought a new stake in Inotiv during the 1st quarter worth about $266,000. Vanguard Group Inc. lifted its position in Inotiv by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 1,043,460 shares of the company’s stock worth $11,415,000 after buying an additional 10,146 shares in the last quarter. Denali Advisors LLC bought a new stake in Inotiv during the 1st quarter worth about $277,000. Finally, KPP Advisory Services LLC lifted its position in Inotiv by 46.4% during the 4th quarter. KPP Advisory Services LLC now owns 166,076 shares of the company’s stock worth $609,000 after buying an additional 52,603 shares in the last quarter. 18.17% of the stock is owned by institutional investors.

Inotiv Company Profile

(Get Free Report)

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.

See Also

Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with MarketBeat.com's FREE daily email newsletter.